BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)

clipboard-pencil

About the study

The purpose of this study is to describe the natural history and progression of patients diagnosed with PH1, and to characterize the long-term real-world safety and effectiveness of lumasiran.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:


* Documented diagnosis of PH1, per physician's determination


EXCLUSION CRITERIA

Exclusion Criteria:


* Currently enrolled in a clinical trial for any investigational agent


pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 1-877-ALNYLAMEmail iconEmail Study Center

Study Details


Contition
Primary Hyperoxaluria Type 1
Participants Needed
200
Est. Completion Date
Sep 1, 2028
Treatment Type
OBSERVATIONAL

Sponsor
Alnylam Pharmaceuticals
ClinicalTrials.gov NCT Identifier
NCT04982393
Study Number
ALN-GO1-007

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to create a personal profile and 
receive news, resources, and alerts 
about clinical trials related to your conditions of interest.